Education
About Us
Working with TipRanks
Follow Us
Cybin (CYBN)
:CYBN
CYBN Stock Chart & Stats
$6.18
-$0.47(-4.69%)
At close: 4:00 PM EST
$6.18
-$0.47(-4.69%)
Day’s Range― - ―
52-Week Range$4.81 - $11.08
Previous Close$9.5
Volume184.55K
Average Volume (3M)657.06K
Market Cap
$1.39M
Enterprise ValueN/A
Total Cash (Recent Filing)$118.69M
Total Debt (Recent Filing)$44.50M
Price to Earnings (P/E)―
Beta0.87
Next Earnings
Feb 17, 2026EPS Estimate
-0.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.39
Shares Outstanding23,590,025
10 Day Avg. Volume589,716
30 Day Avg. Volume657,064
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$44.25Price Target Upside616.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsCYB003, in major depressive disorder, showed durable Phase 2 efficacy with an average 23-point reduction in Montgomery–Åsberg Depression Rating Scale scores and 71% remission at 12 months after two 16 mg doses.
Financial StabilityThe recent capital raise provides CYBN with a cash runway into 2027, allowing the company to focus on its strategic goals.
Pipeline DevelopmentCYB004 approaching a key inflection point, with completed enrollment in the Phase 2a trial in generalized anxiety disorder positioning the upcoming readout as a catalyst that could reshape investor perception of DMT programs.
Bears Say
Increased Share CountThe increased share count from the recent financing, normalization of expenses in the model, and fine-tuning the expected CYB003 and CYB004 launches resulted in a revised $55 price target from $150.
Price Target ReductionThe updated model includes a reduced price target from $70 to $45, mainly due to dilution from the recent capital raise.
Cybin News
CYBN FAQ
What was Cybin’s price range in the past 12 months?
Cybin lowest stock price was $4.81 and its highest was $11.08 in the past 12 months.
What is Cybin’s market cap?
Cybin’s market cap is $1.39M.
When is Cybin’s upcoming earnings report date?
Cybin’s upcoming earnings report date is Feb 17, 2026 which is in 78 days.
How were Cybin’s earnings last quarter?
Cybin released its earnings results on Nov 13, 2025. The company reported -$1.394 earnings per share for the quarter, missing the consensus estimate of -$1.041 by -$0.352.
Is Cybin overvalued?
According to Wall Street analysts Cybin’s price is currently Undervalued.
Does Cybin pay dividends?
Cybin does not currently pay dividends.
What is Cybin’s EPS estimate?
Cybin’s EPS estimate is -0.58.
How many shares outstanding does Cybin have?
Cybin has 23,590,025 shares outstanding.
What happened to Cybin’s price movement after its last earnings report?
Cybin reported an EPS of -$1.394 in its last earnings report, missing expectations of -$1.041. Following the earnings report the stock price went down -8.05%.
Which hedge fund is a major shareholder of Cybin?
Currently, no hedge funds are holding shares in CYBN
Company Description
Cybin
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.
CYBN Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a company making significant progress in advancing its clinical programs and strengthening its financial position, despite facing challenges such as leadership transition and increased expenses. The overall sentiment is balanced, with solid achievements in clinical and operational fronts but offset by financial and leadership concerns.View all CYBN earnings summariesCYBN Stock 12 Month Forecast
Average Price Target
$44.25
▲(616.02% Upside)